Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
CEMATRIX Corp
T.CEMX
Alternate Symbol(s):
CTXXF
Industrials
Engineering & Construction
CEMATRIX Corporation is a Canada-based company, which manufactures and supplies technologically advanced cellular concrete products developed from proprietary formulations across North America. It is engaged in the supply and placement of cellular concrete. The Company’s cement-based material with thermal protection, which delivers a range of problems facing the infrastructure, industrial, energy and commercial markets. It supplies and installs lightweight cellular concrete with a cast density as low as 400 kg/m3. Its cellular concrete is commonly used as an insulation material for oil and gas facility slabs, roadways, shallow utilities and contaminated site remediation that requires ground heating. Its applications include retaining wall and bridge approach backfill, roadways and runways, and slope stabilization. Its wholly owned operating subsidiaries include CEMATRIX (Canada) Inc. (CCI), MixOnSite USA Inc. and Pacific International Grout Company.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
TSX:CEMX - Post by User
CEMATRIX Corp
<< Previous
Bullboard Posts
Next >>
(201)
•••
Hunk33
X
View Profile
View Bullboard History
Post by
Hunk33
on May 15, 2024 3:43pm
93 Views
Post# 36041848
Its painfully to see CVX tumbling from .44 c to .34c
Its painfully to see CVX tumbling from .44 c to .34c
The only nigative news was , annoucing couple times 17md contract being canceled,CVX should never mention that, this is the reason behind CVX tumbling of cliff from .44c to .34c its sad.
Comment on this Post
<< Previous
Bullboard Posts
Next >>
Invest wiser with BMO's InvestorLine Platform features
A potential breakthrough in spinal cord and optic nerve injury treatment
Eminent acquires promising Nevada gold project
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide
NervGen Pharma: Proof that NVG-291 works?
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight